natgillin/translations-raw huggingface dataset:
For the full list of side effects reported with Spectrila, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Spectrila, glejte navodilo za uporabo.
The active substance in Spectrila, asparaginase, is an enzyme that works by breaking up and reducing the blood levels of the amino acid asparagine. 
Zdravilna učinkovina zdravila Spectrila, asparaginaza, je encim, ki razgrajuje aminokislino asparagin in zmanjšuje njeno koncentracijo v krvi.
How is Spectrila used? 
Kako se zdravilo Spectrila uporablja?
Spectrila is used in adults and children to treat acute lymphoblastic leukaemia (ALL), a cancer of white blood cells called lymphoblasts, in combination with other cancer medicines. 
Spectrila je zdravilo za zdravljenje akutne limfoblastne levkemije (ALL), vrste raka belih krvnih celic, imenovanih limfoblasti.
Only healthcare professionals experienced in cancer treatments should prescribe and give Spectrila. 
Zdravilo Spectrila lahko predpisujejo in dajejo samo zdravniki, ki imajo izkušnje z zdravljenjem raka.
Spectrila can only be obtained with a prescription and is available in a vial as a powder to be made into a solution for infusion. 
Na voljo je v viali kot prašek za pripravo raztopine za infundiranje.
Strength Pharmaceutical Form Route of administration Packaging 
Številka EU Izmišljeno ime Jakost Farmacevtska oblika
EU Numbers 
Ovojnina
Invented name 
Pot uporabe
• Clear information about their difference in concentration. 
• Jasne informacije o razliki v koncentraciji.
• Encouragement to report medications errors and their causes and consequences. 
• Spodbudo za prijavljanje napak pri zdravljenju, njihovih vzrokih in posledicah.
• Information about the potential safety risks of errors in dosing calculation resulting from the confusion between the two formulations and its possible clinical consequences (e.g. potential for thrombotic risk if overdose). 
• Informacije o možnih varnostnih tveganjih zaradi napak v odmerjanju, ki bi se pojavile zaradi nerazlikovanja med obema formulacijama, in o možnih kliničnih posledicah (npr. o možnem tveganju za trombozo v primeru prevelikega odmerjanja).
The Marketing Authorisation Holder must implement this educational plan nationally, prior to marketing, and as agreed with the competent authorities in the Member States. 
Imetnik dovoljenja za promet mora ta načrt izobraževanja izvesti na državni ravni, pred prihodom nove formulacije na trg in v soglasju s pristojnimi organi Držav članic.
The patient information pack to be used by healthcare professionals in the education of the patients should contain the same above described key elements. 
¸Komplet informacij za bolnike, ki ga bodo zdravstveni delavci uporabili za izobraževanje bolnikov, mora prav tako vključevati vse zgoraj opisane ključne elemente.
• Clear demarcation of the new formulation of NovoSeven from original NovoSeven, with clear descriptions of any differences in the vial sizes, colour codes and dosing and reconstitution instructions 
• Jasno razmejitev med novo formulacijo NovoSeven in prvotnim NovoSeven z jasnim opisom vseh razlik v velikosti vial, barvnem kodiranju ter navodilih za odmerjanje in rekonstitucijo.
Both information packs are to be used as part of an educational plan provided to minimise risk of medication errors that may be associated with the change in concentration of the new Novoseven formulation. 
Oba izobraževalna kompleta je treba uporabiti v okviru načrta izobraževanja, namenjenega zmanjšanju tveganja za napake pri uporabi zdravila, ki bi se lahko pojavile zaradi spremenjene koncentracije nove formulacije NovoSeven.
The physician information should contain the following key elements: 
Informacije za zdravnike morajo vključevati naslednje ključne elemente:
• Dosing reference card 
• Referenčno kartico za odmerjanje
The Marketing Authorisation Holder (MAH) shall ensure that, at launch, all physicians who are expected to prescribe/use NovoSeven are provided with an Educational pack containing the following: 
Imetnik dovoljenja za promet zagotavlja, da bodo ob prihodu zdravila na trg vsi zdravniki, ki bodo predvidoma predpisovali oz. uporabljali NovoSeven, dobili izobraževalno gradivo.
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO VPELJATI DRŽAVE ČLANICE
• Letter to healthcare professionals 
• Pismo zdravnikom
• Summary leaflet of the product features and reconstitution guide, including highlighted changes that have been made for the new formulation of NovoSeven. 
• Povzetek lastnosti zdravila in navodilo za rekonstitucijo s poudarjenimi spremembami,
The Member States shall ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented: 
Države članice morajo zagotoviti, da bodo vpeljeni vsi spodaj opisani pogoji ali omejitve v zvezi z varno in učinkovito uporabo zdravila,
The physician information pack should contain the following: 
Komplet informacij za zdravnike mora vsebovati:
• Educational slide kit 
• Izobraževalni komplet prosojnic
• Question & Answer booklet 
• Knjižico z vprašanji in odgovori
• Physician information pack 
• komplet informacij za zdravnike
It may harm them, 
ki ga še prenašajo:
Date of first authorisation: 01 December 2008 Date of latest renewal: 31 July 2013 
Datum prve odobritve: 01. december 2008 Datum zadnjega podaljšanja: 31 julij 2013
However, this has not been established in the target population. 
Vendar pa le-teh niso ugotavljali pri ciljni populaciji.
These changes are not considered to be clinically relevant, however. 
Vendar te spremembe ne veljajo za klinično pomembne.
The absolute bioavailability is 85%. 
Absolutna biološka uporabnost je 85 %.
Medical attention may be necessary. 
Morda bo potrebna zdravniška pomoč.
The mean volume of distribution (Vd) ranged between 63-276 litres. 
Povprečni volumen porazdelitve (Vd) je bil v okviru 63-276 litrov.
PA/Alu/PVC/Alu 2 years PCTFE/PVC/Alu 18 months 
PA/Alu/PVC/Alu 2 leti PCTFE/PVC/Alu 18 mesecev
The amount of Zomarist that people have to take varies depending on their condition. 
Koliko zdravila Zomarist morajo ljudje jemati, je odvisno od njihovega stanja.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah,objavljenih na evropskem spletnem portalu o zdravilih.
Supportive management is recommended. 
Priporočeno je podporno zdravljenje.
However, the magnitude of change is not clinically significant, so that vildagliptin can be given with or without food. 
Vendar pa velikost te spremembe ni klinično pomembna, zato se lahko vildagliptin uživa s hrano ali brez nje.
What Zomarist is and what it is used for 
Kaj je zdravilo Zomarist in za kaj ga uporabljamo
Cardiovascular risk 
Kardiovaskularno tveganje
Pregnancy and breast-feeding - If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Nosečnost in dojenje - Če ste noseči, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
Type 2 diabetes develops if the body does not make enough insulin or if the insulin that the body makes does not work as well as it should. 
Diabetes tipa 2 se razvije v primeru, ko organizem ne tvori dovolj insulina, ali pa če insulin, ki ga organizem tvori, ne deluje tako, kot bi moral.
If you have any questions about how long to take this medicine, talk to your doctor. 
Če vas zanima, kako dolgo morate jemati to zdravilo, se pogovorite s svojim zdravnikom.
Frequencies are defined as very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). 
Pogostnosti so definirane kot: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
In patients at increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months. 
Pri bolnikih s povečanim tveganjem dodatnega napredovanja okvare ledvic in pri starejših je treba delovanje ledvic oceniti pogosteje, na primer vsake 3 do 6 mesecev.
Taking the tablet just after food will lower the risk of an upset stomach. 
Jemanje tablete takoj po hrani bo zmanjšalo možnost želodčnih težav.
Do not take Zomarist - if you are allergic to vildagliptin, metformin or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Zomarist - če ste alergični na vildagliptin, metformin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
The clinical relevance of this decrease is unknown. 
Klinični pomen tega vpliva ni znan.
This is so that signs of increased liver enzymes can be detected as early as possible. 
To je potrebno za čimprejšnje odkrivanje znakov zvišanih vrednosti jetrnih encimov.
Insulin helps to lower the level of sugar in the blood, especially after meals. 
Insulin pomaga zniževati koncentracijo sladkorja v krvi, posebno po obrokih.
A slow increase in the dose may also improve gastrointestinal tolerability. 
Tudi počasno zviševanje odmerka lahko izboljša gastrointestinalno prenosljivost zdravila.
If no adequate strength of Zomarist is available, individual monocomponents should be used instead of the fixed dose combination. 
Če ni na voljo ustrezna jakost zdravila Zomarist, je treba namesto fiksne kombinacije uporabiti posamične monokomponente.
If you have to go to a doctor or hospital, take the pack and this leaflet with you. 
Če morate k zdravniku oziroma v bolnišnico, vzemite škatlo zdravil in ta navodila s seboj.
To prevent them, it is recommended that metformin be taken in 2 daily doses during or after meals. 
Za preprečevanje teh učinkov je priporočeno jemanje metformina v 2 odmerkih dnevno in sicer med obrokom ali takoj po njem.
Gastrointestinal adverse reactions occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
Do gastrointestinalnih neželenih učinkov pride najpogosteje na začetku zdravljenja in v večini primerov spontano izzvenijo.
If you have previously taken vildagliptin but had to stop taking it because of liver disease, you should not take this medicine. 
Če ste vildagliptin že jemali, pa ste ga morali prenehati zaradi bolezni jeter, ne smete jemati tega zdravila.
Ketoacidosis is a condition in which substances called ketone bodies accumulate in the blood and which can lead to diabetic pre-coma. 
Ketoacidoza je stanje, pri katerem se snovi, imenovane ketonska telesa, kopičijo v krvi, kar lahko povzroči diabetično predkomo.
Plasma protein binding is negligible. 
Obseg vezave na plazemske proteine je zanemarljiv.
Your doctor will discuss with you the potential risk of taking Zomarist during pregnancy. 
Zdravnik vam bo pojasnil možna tveganja zaradi jemanja zdravila Zomarist med nosečnostjo.
They were reversible despite continued treatment and were not associated with histopathological abnormalities. 
Ti so bili reverzibilni kljub nadaljevanju zdravljenja in jih niso spremljale histopatološke nepravilnosti.
These were consistently located on the extremities (hands, feet, ears and tail). 
Te spremembe so dosledno opažali na udih (rokah, stopalih, uhljih in repu).
Food slightly delays the time to peak plasma concentration to 2.5 hours, but does not alter the overall exposure (AUC). 
Hrana nekoliko podaljša čas do najvišje plazemske koncentracije na 2,5 ure, ne spremeni pa celotne izpostavljenosti zdravilu (AUC).
Food does not affect the extent and rate of absorption of vildagliptin from Zomarist. 
Hrana ne vpliva na obseg in hitrost absorpcije vildagliptina iz zdravila Zomarist.
There are no adequate data from the use of Zomarist in pregnant women. 
Ni zadostnih podatkov o uporabi zdravila Zomarist pri nosečnicah.
What you need to know before you take Zomarist 
Kaj morate vedeti, preden boste vzeli zdravilo Zomarist
Not all pack sizes and tablet strengths may be available in your country. 
V vaši državi morda niso na voljo vse velikosti pakiranj in jakosti tablet.
The substance metformin works by helping the body to make better use of insulin. 
Učinkovina metformin deluje tako, da pomaga organizmu bolje izrabiti insulin.
C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose was recovered in the faeces. 
C označenega vildagliptina se je približno 85 % odmerka izločilo z urinom, 15 % odmerka pa so našli v blatu.
A GFR should be assessed before initiation of treatment with metformin-containing products and at least annually thereafter. 
GFR je treba oceniti pred uvedbo zdravljenja z zdravili, ki vsebujejo metformin, nato pa vsaj enkrat letno.
The following statements reflect the pharmacokinetic properties of the individual active substances of Zomarist. 
Naslednje trditve opisujejo farmakokinetične lastnosti posameznih učinkovin zdravila Zomarist.
GFR should be assessed before treatment initiation and regularly thereafter (see section 4.2). 
GFR je treba oceniti pred uvedbo zdravljenja, nato pa v rednih presledkih (glejte poglavje 4.2).
If you forget to take a tablet, take it with your next meal unless you are due to take one then anyway. 
Če ste pozabili vzeti tableto, jo vzemite z naslednjim obrokom, razen če je že čas, da vzamete naslednjo tableto.
Use of vildagliptin has beenassociated with a risk of developing of acute pancreatitis. 
Uporabo vildagliptina povezujejo s tveganjem za razvoj akutnega pankreatitisa.
The European Medicines Agency has waived the obligation to submit the results of studies with vildagliptin in combination with metformin in all subsets of the paediatric population with type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z vildagliptinom v kombinaciji z metforminom za vse podskupine pediatrične populacije s sladkorno boleznijo tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Patients should be informed of the characteristic symptom of acute pancreatitis. 
Bolnike je potrebno obvestiti o značilnem simptomu akutnega pankreatitisa.
Ethnic group: Limited data suggest that race does not have any major influence on vildagliptin pharmacokinetics. 
Etnična pripadnost: Podatki omejenega obsega nakazujejo, da rasna pripadnost nima pomembnega vpliva na farmakokinetiko vildagliptina.
Metformin must be discontinuedat the time of surgery under general, spinal or epidural anaesthesia. 
Uporabo metformina je treba v času kirurškega posega pod splošno, spinalno ali epiduralno anestezijo prekiniti.
Since this product has been marketed, the following side effects have also been reported: 
Odkar je zdravilo na trgu, so poročali tudi o naslednjem neželenem učinku
You are advised to follow the recommendations for skin and foot care that you are given by your doctor or nurse. 
Priporočamo vam, da se držite navodil za nego kože in stopal, kot vam jih priporoča vaš zdravnik ali medicinska sestra.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC ODGOVOREN ZA SPROŠČANJE SERIJ
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) 
VMESNA ŠKATLA PRI SKUPNEM PAKIRANJU (BREZ "BLUE BOX" PODATKOV)
During treatment with Zomarist, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or have worsening renal function. 
Med zdravljenjem z zdravilom Zomarist bo zdravnik vsaj enkrat letno preveril delovanje ledvic, če pa ste starejša oseba in/ali se vam delovanje ledvic slabša, pa še pogosteje.
After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%. 
Po peroralnem odmerjanju je neabsorbirani delež v blatu znašal 20-30 %.
Continue to follow any advice about diet that your doctor has given you. 
Še naprej se držite diete, ki vam jo je priporočil zdravnik.
Your doctor may prescribe this medicine alone or with certain other medicines that lower the level of sugar in your blood. 
Zdravnik vam lahko predpiše, da jemljete to zdravilo samostojno ali pa skupaj z določenimi drugimi zdravili, ki znižujejo raven sladkorja v krvi.
All symptoms and laboratory abnormalities resolved without treatment after discontinuation of the study medicinal product. 
Vsi simptomi in nenormalni laboratorijski izvidi so izzveneli brez zdravljenja po prekinitvi jemanja preiskovanega zdravila.
Other medicines and Zomarist 
Druga zdravila in zdravilo Zomarist
The safety and efficacy of Zomarist in children and adolescents (< 18 years) have not been established. 
Varnost in učinkovitost zdravila Zomarist pri otrocih in mladostnikih (< 18 let) nista bili dokazani.
The prospective randomised UKPDS (UK Prospective Diabetes Study) study has established the longterm benefit of intensive blood glucose control in type 2 diabetes. 
V prospektivni randomizirani študiji UKPDS (UK Prospective Diabetes Study - Britanska prospektivna študija diabetesa) so ugotovili dolgoročno koristnost intenzivnega uravnavanja koncentracije glukoze pri diabetesu tipa 2.
Your doctor will tell you exactly the dose of Zomarist to take. 
Zdravnik vam bo natančno povedal, kolikšen odmerek zdravila Zomarist morate jemati.
The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment. 
Bolnik mora biti o tem poučen, koncentracijo glukoze v krvi pa je treba meriti pogosteje, še posebno na začetku zdravljenja.
Therefore, vildagliptin is not likely to affect metabolic clearance of co-medications metabolised by CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 or CYP 3A4/5. 
Zato ni verjetno, da bi vildagliptin vplival na presnovni očistek sočasno uporabljanih zdravil, ki se presnavljajo z encimi CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 ali CYP 3A4/5.
Do not stop taking Zomarist unless your doctor tells you to. 
Ne prenehajte jemati zdravila Zomarist, če vam tega ne naroči zdravnik.
Three other subjects experienced oedema of the feet, with paraesthesia in two cases. 
Pri treh drugih osebah je prišlo do otekanja stopal, v dveh primerih s parestezijo.
In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 4 µg/ml, even at maximum doses. 
V kontroliranih kliničnih preskušanjih najvišje koncentracije metformina v plazmi (Cmax) niso presegale 4 µg/ml niti pri najvišjih odmerkih.
In vitro studies demonstrated that vildagliptin does not inhibit/induce CYP 450 enzymes. 
In vitro študije so pokazale, da vildagliptin ne zavira/inducira encimov CYP 450.
Diagnostic laboratory findings are decreased blood pH (< 7.35), increased plasma lactate levels (> 5 mmol/l) and an increased anion gap and lactate/pyruvate ratio. 
Diagnostični laboratorijski izvidi so zmanjšan pH krvi (< 7,35), zvišane ravni laktata v plazmi (> 5 mmol/l) in povečana anionska vrzel ter razmerje laktat/piruvat.
Findings were only observed in association with maternal toxicity at ≥ 150 mg/kg and included a transient decrease in body weight and reduced motor activity in the F1 generation. 
Učinke so opažali samo v povezavi s toksičnostjo za mater pri odmerkih ≥ 150 mg/kg, vključevali pa so prehodno zmanjšanje telesne mase in zmanjšano motorično aktivnost v F1 generaciji.
The following statements reflect the information available on the individual active substances. 
Naslednje trditve odražajo podatke, ki so na voljo za obe posamezni zdravilni učinkovini.
Glucocorticoids, beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity. 
Glukokortikoidi, beta-2 agonisti in diuretiki imajo intrinzično hiperglikemično aktivnost.
It is assumed that the pharmacokinetics of metformin absorption are non-linear. 
Domnevajo, da je farmakokinetika absorpcije metformina nelinearna.
Sulphonylureas are known to cause hypoglycaemia. 
Znano je, da sulfoniluree povzročajo hipoglikemijo.
Information on the likely symptoms of overdose with vildagliptin was taken from a rising dose tolerability study in healthy subjects given vildagliptin for 10 days. 
Podatki o verjetnih simptomih prevelikega odmerjanja vildagliptina temeljijo na študiji prenašanja naraščajočih odmerkov, izvedeni na zdravih osebah, ki so prejemale vildagliptin 10 dni.
Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes. 
Ker vildagliptin ni niti substrat encimov citokroma P (CYP) 450 niti ne zavira ali inducira encimov CYP 450, ni verjetno, da bi prišlo do interakcij z učinkovinami, ki so substrati, zaviralci ali induktorji teh encimov.
No association was found between adverse reactions and age, ethnicity, duration of exposure or daily dose. 
Povezave med neželenimi učinki in starostjo, etnično pripadnostjo, trajanjem zdravljenja ali velikostjo dnevnega odmerka niso ugotovili.
Taking Zomarist with or just after food may reduce gastrointestinal symptoms associated with metformin (see also section 5.2). 
Jemanje zdravila Zomarist s hrano ali takoj po njej lahko ublaži gastrointestinalne simptome, ki so povezani z jemanjem metformina (glejte tudi poglavje 5.2).
Combination with a sulphonylurea 
Kombinacija s sulfonilureo
OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX) 
ZUNANJA ŠKATLA SKUPNEGA PAKIRANJA (VKLJUČNO Z "BLUE BOX" PODATKI)
These elevations in transaminases were generally asymptomatic, non-progressive in nature and not associated with cholestasis or jaundice. 
Ta zvišanja vrednosti aminotransferaz so bila večinoma asimptomatska, neprogresivne narave in niso bila povezana s holestazo ali z ikterusom.
Should these occur, you should promptly consult your doctor. 
Če pride do teh sprememb, takoj obvestite svojega zdravnika.
Diabetic skin lesions are a common complication of diabetes. 
Diabetične spremembe na koži so pogost diabetični zaplet.
A study in healthy volunteers showed that cimetidine, administered as 400 mg twice daily, increased metformin systemic exposure (AUC) by 50%. 
V študiji na zdravih prostovoljcih se je pokazalo, da je uporaba cimetidina v odmerku 400 mg dvakrat na dan povečala sistemsko izpostavljenost metforminu (AUC) za 50 %.
You may need more frequent blood glucose and kidney function tests or your doctor may need to adjust the dosage of Zomarist. 
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Zomarist.
The following data are findings from studies performed with vildagliptin or metformin individually. 
Naslednji podatki so izsledki študij, ki so jih izvajali ločeno z vildagliptinom ali metforminom.
No new toxicities associated with the combination were identified. 
Pri tem niso ugotovili nobenega novega toksičnega vpliva, povezanega s kombinacijo učinkovin.
Biotransformation Metformin is excreted unchanged in the urine. 
Biotransformacija Metformin se izloča z urinom v nespremenjeni obliki.
Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD08 
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, kombinacije peroralnih antidiabetikov, oznaka ATC: A10BD08
10 film-coated tablets 30 film-coated tablets 60 film-coated tablets 120 film-coated tablets 180 film-coated tablets 360 film-coated tablets 
10 filmsko obloženih tablet 30 filmsko obloženih tablet 60 filmsko obloženih tablet 120 filmsko obloženih tablet 180 filmsko obloženih tablet 360 filmsko obloženih tablet